Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 6/2011

01.06.2011 | Original Article

Sleeve Gastrectomy with Ileal Transposition (SGIT) Induces a Significant Weight Loss and Diabetes Improvement Without Exclusion of the Proximal Intestine

verfasst von: Camilo Boza, Rodrigo Muñoz, Elliot Yung, Luca Milone, Michel Gagner

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Current effective bariatric procedures such as gastric bypass generate a duodenal–jejunal exclusion, which has been implicated in the resolution of type 2 diabetes. The aim of this study was to test the hypothesis that sleeve gastrectomy with ileal transposition (SGIT), a new procedure, is as effective as Roux-en-Y gastric bypass (RYGB) to induce glucose control on an obese rat model of type 2 diabetes mellitus.

Methods

Twenty eight obese diabetic Zucker rats, weighing 571 ± 151 g were assigned into three procedures: SGIT (n = 11), RYGB (n = 7), and sham operation (n = 10). Animals were followed, evaluating weekly weight increase and food intake. We performed an insulin tolerance test after 8 weeks and measured serum peptide tyrosine–tyrosine (PYY 3-36) and ghrelin levels.

Results

Nine weeks after surgery, sham-operated animals increased their body weight by 24%. In far contrast, SGIT and RYGB rats weighed 21% and 18% less than sham animals, respectively (sham, 884 ± 15 g; SGIT, 720 ± 19 g; RYGB, 754 ± 14 g; p < 0.001). No significant differences were found between SGIT and RYGB. Cumulative food intake in SGIT and RYGB procedures decreased by 29.6% and 32.9%, respectively (sham, 576.3 ± 33 g; SGIT, 405.8 ± 10 g; RYGB, 386.4 ± 21 g; p < 0.001). No differences were found between SGIT and RYGB rats. Sixty minutes after oral gavage, PYY levels were increased by 185% and 74% in SGIT and RYGB, respectively (sham, 63.4 ± 2.1 pg/ml; SGIT, 192.7 ± 17 pg/ml; RYGB, 117.7 ± 4.8 pg/ml; p < 0.001). Glucose tolerance was improved after SGIT and RYGB surgery demonstrated by area under the curve analysis (sham, 27,090 ± 1,424; SGIT, 17,704 ± 1,288 mg/dl; p < 0.018; RYGB, 16,212 ± 2,522; p < 0.01).

Conclusion

SGIT proved to be as effective as RYGB on obese diabetic rats as a weight loss procedure. Also, glucose homeostasis improved in SGIT, similar to RYGB, in spite of the absence of duodenal–jejunal exclusion. This observation does not support the theory that RYGB reversal of diabetes is due to duodenal–jejunal exclusion.
Literatur
1.
Zurück zum Zitat Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med 2009;122:248–256 e245.PubMedCrossRef Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med 2009;122:248–256 e245.PubMedCrossRef
2.
Zurück zum Zitat Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D: Effect of laparoscopic roux-en y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467–484; discussion 484–465.PubMed Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D: Effect of laparoscopic roux-en y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467–484; discussion 484–465.PubMed
3.
Zurück zum Zitat Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339–350; discussion 350–332.PubMedCrossRef Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339–350; discussion 350–332.PubMedCrossRef
4.
Zurück zum Zitat Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS: Loss of insulin resistance after roux-en-y gastric bypass surgery: A time course study. Obes Surg 2005;15:474–481.PubMedCrossRef Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS: Loss of insulin resistance after roux-en-y gastric bypass surgery: A time course study. Obes Surg 2005;15:474–481.PubMedCrossRef
5.
Zurück zum Zitat Marceau P, Hould FS, Simard S, Lebel S, Bourque RA, Potvin M, Biron S: Biliopancreatic diversion with duodenal switch. World J Surg 1998;22:947–954.PubMedCrossRef Marceau P, Hould FS, Simard S, Lebel S, Bourque RA, Potvin M, Biron S: Biliopancreatic diversion with duodenal switch. World J Surg 1998;22:947–954.PubMedCrossRef
6.
Zurück zum Zitat Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, Camerini G, Baschieri G, Simonelli A: Biliopancreatic diversion. World J Surg 1998;22:936–946.PubMedCrossRef Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, Camerini G, Baschieri G, Simonelli A: Biliopancreatic diversion. World J Surg 1998;22:936–946.PubMedCrossRef
7.
Zurück zum Zitat Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J: Outcomes after laparoscopic roux-en-y gastric bypass for morbid obesity. Ann Surg 2000;232:515–529.PubMedCrossRef Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J: Outcomes after laparoscopic roux-en-y gastric bypass for morbid obesity. Ann Surg 2000;232:515–529.PubMedCrossRef
8.
Zurück zum Zitat Cowan GS, Jr., Buffington CK: Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg 1998;22:987–992.PubMedCrossRef Cowan GS, Jr., Buffington CK: Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg 1998;22:987–992.PubMedCrossRef
9.
Zurück zum Zitat Cummings DE: Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009;33 Suppl 1:S33–40.CrossRef Cummings DE: Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009;33 Suppl 1:S33–40.CrossRef
10.
Zurück zum Zitat Rubino F, Marescaux J: Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: A new perspective for an old disease. Ann Surg 2004;239:1–11.PubMedCrossRef Rubino F, Marescaux J: Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: A new perspective for an old disease. Ann Surg 2004;239:1–11.PubMedCrossRef
11.
Zurück zum Zitat Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J: The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244:741–749.PubMedCrossRef Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J: The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244:741–749.PubMedCrossRef
12.
Zurück zum Zitat Strader AD, Vahl TP, Jandacek RJ, Woods SC, D’Alessio DA, Seeley RJ: Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005;288:E447–453.PubMedCrossRef Strader AD, Vahl TP, Jandacek RJ, Woods SC, D’Alessio DA, Seeley RJ: Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005;288:E447–453.PubMedCrossRef
13.
Zurück zum Zitat Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, Donini A: Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 2005;15:1258–1264.PubMedCrossRef Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, Donini A: Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 2005;15:1258–1264.PubMedCrossRef
14.
Zurück zum Zitat Wang TT, Hu SY, Gao HD, Zhang GY, Liu CZ, Feng JB, Frezza EE: Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type ii diabetes by increasing glp-1. Ann Surg 2008;247:968–975.PubMedCrossRef Wang TT, Hu SY, Gao HD, Zhang GY, Liu CZ, Feng JB, Frezza EE: Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type ii diabetes by increasing glp-1. Ann Surg 2008;247:968–975.PubMedCrossRef
15.
Zurück zum Zitat Strader AD, Clausen TR, Goodin SZ, Wendt D: Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg 2009;19:96–104.PubMedCrossRef Strader AD, Clausen TR, Goodin SZ, Wendt D: Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg 2009;19:96–104.PubMedCrossRef
16.
Zurück zum Zitat Boza C, Gagner M, Devaud N, Escalona A, Munoz R, Gandarillas M: Laparoscopic sleeve gastrectomy with ileal transposition (sgit): A new surgical procedure as effective as gastric bypass for weight control in a porcine model. Surg Endosc 2008;22:1029–1034.PubMedCrossRef Boza C, Gagner M, Devaud N, Escalona A, Munoz R, Gandarillas M: Laparoscopic sleeve gastrectomy with ileal transposition (sgit): A new surgical procedure as effective as gastric bypass for weight control in a porcine model. Surg Endosc 2008;22:1029–1034.PubMedCrossRef
17.
Zurück zum Zitat Guijarro A, Suzuki S, Chen C, Kirchner H, Middleton FA, Nadtochiy S, Brookes PS, Niijima A, Inui A, Meguid MM: Characterization of weight loss and weight regain mechanisms after roux-en-y gastric bypass in rats. Am J Physiol Regul Integr Comp Physiol 2007;293:R1474–1489.PubMedCrossRef Guijarro A, Suzuki S, Chen C, Kirchner H, Middleton FA, Nadtochiy S, Brookes PS, Niijima A, Inui A, Meguid MM: Characterization of weight loss and weight regain mechanisms after roux-en-y gastric bypass in rats. Am J Physiol Regul Integr Comp Physiol 2007;293:R1474–1489.PubMedCrossRef
18.
Zurück zum Zitat Stylopoulos N, Hoppin AG, Kaplan LM: Roux-en-y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring) 2009;17:1839–1847.CrossRef Stylopoulos N, Hoppin AG, Kaplan LM: Roux-en-y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring) 2009;17:1839–1847.CrossRef
19.
Zurück zum Zitat Melissas J, Koukouraki S, Askoxylakis J, Stathaki M, Daskalakis M, Perisinakis K, Karkavitsas N: Sleeve gastrectomy: A restrictive procedure? Obes Surg 2007;17:57–62.PubMedCrossRef Melissas J, Koukouraki S, Askoxylakis J, Stathaki M, Daskalakis M, Perisinakis K, Karkavitsas N: Sleeve gastrectomy: A restrictive procedure? Obes Surg 2007;17:57–62.PubMedCrossRef
20.
Zurück zum Zitat Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR: Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650–654.PubMedCrossRef Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR: Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650–654.PubMedCrossRef
21.
Zurück zum Zitat Van Citters GW, Lin HC: The ileal brake: A fifteen-year progress report. Curr Gastroenterol Rep 1999;1:404–409.PubMedCrossRef Van Citters GW, Lin HC: The ileal brake: A fifteen-year progress report. Curr Gastroenterol Rep 1999;1:404–409.PubMedCrossRef
22.
Zurück zum Zitat Naslund E, Hellstrom PM, Kral JG: The gut and food intake: An update for surgeons. J Gastrointest Surg 2001;5:556–567.PubMedCrossRef Naslund E, Hellstrom PM, Kral JG: The gut and food intake: An update for surgeons. J Gastrointest Surg 2001;5:556–567.PubMedCrossRef
23.
Zurück zum Zitat Stylopoulos N, Davis P, Pettit JD, Rattner DW, Kaplan LM: Changes in serum ghrelin predict weight loss after roux-en-y gastric bypass in rats. Surg Endosc 2005;19:942–946.PubMedCrossRef Stylopoulos N, Davis P, Pettit JD, Rattner DW, Kaplan LM: Changes in serum ghrelin predict weight loss after roux-en-y gastric bypass in rats. Surg Endosc 2005;19:942–946.PubMedCrossRef
24.
Zurück zum Zitat Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623–1630.PubMedCrossRef Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623–1630.PubMedCrossRef
25.
Zurück zum Zitat Leonetti F, Silecchia G, Iacobellis G, Ribaudo MC, Zappaterreno A, Tiberti C, Iannucci CV, Perrotta N, Bacci V, Basso MS, Basso N, Di Mario U: Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab 2003;88:4227–4231.PubMedCrossRef Leonetti F, Silecchia G, Iacobellis G, Ribaudo MC, Zappaterreno A, Tiberti C, Iannucci CV, Perrotta N, Bacci V, Basso MS, Basso N, Di Mario U: Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab 2003;88:4227–4231.PubMedCrossRef
26.
Zurück zum Zitat Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K: Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594–1602.PubMedCrossRef Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K: Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594–1602.PubMedCrossRef
27.
Zurück zum Zitat Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA: Ghrelin and adipose tissue regulatory peptides: Effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003;88:3177–3183.PubMedCrossRef Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA: Ghrelin and adipose tissue regulatory peptides: Effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003;88:3177–3183.PubMedCrossRef
28.
Zurück zum Zitat Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flue M, Beglinger C: Improvement in glucose metabolism after bariatric surgery: Comparison of laparoscopic roux-en-y gastric bypass and laparoscopic sleeve gastrectomy: A prospective randomized trial. Ann Surg 2009;250:234–241.PubMedCrossRef Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flue M, Beglinger C: Improvement in glucose metabolism after bariatric surgery: Comparison of laparoscopic roux-en-y gastric bypass and laparoscopic sleeve gastrectomy: A prospective randomized trial. Ann Surg 2009;250:234–241.PubMedCrossRef
29.
Zurück zum Zitat Kumar KV, Ugale S, Gupta N, Naik V, Kumar P, Bhaskar P, Modi KD: Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes Technol Ther 2009;11:785–789.PubMedCrossRef Kumar KV, Ugale S, Gupta N, Naik V, Kumar P, Bhaskar P, Modi KD: Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes Technol Ther 2009;11:785–789.PubMedCrossRef
Metadaten
Titel
Sleeve Gastrectomy with Ileal Transposition (SGIT) Induces a Significant Weight Loss and Diabetes Improvement Without Exclusion of the Proximal Intestine
verfasst von
Camilo Boza
Rodrigo Muñoz
Elliot Yung
Luca Milone
Michel Gagner
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 6/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1369-6

Weitere Artikel der Ausgabe 6/2011

Journal of Gastrointestinal Surgery 6/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.